Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2Phase 3 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Breast Neoplasms 547Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 332Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 260Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 203Carcinoma, Hepatocellular 196Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 132Glioblastoma 131Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 124Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

ruxolitinib 1Lisaftoclax 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Prolymphocytic, T-Cell × 1 year × Clear all
NCT07356245 2026-04-15

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
44 enrolled
DermatologicLymphoidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡